The management of metastatic radioiodine-refractory differentiated thyroid cancer requires an integrated approach including both directed and systemic therapies
A 58-year-old man with metastatic radioiodine-refractory differentiated thyroid cancer (DTC) presented with left thigh and right flank numbness. He had known progressive and widespread bony metastases, for which he received palliative radiotherapy, and multiple bilateral asymptomatic pulmonary metas...
Main Authors: | Shamil D Cooray, Duncan J Topliss |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2017-02-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-16-0089 |
Similar Items
-
Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01) -
Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01) -
THE RESOLUTION OF THE EXPERT COUNCIL FOR TARGETED THERAPY OF RADIOIODINE REFRACTORY DIFFERENTIATED THYROID CANCER
by: . Expert Council
Published: (2015-04-01) -
Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01) -
Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)